Express Scripts acquires myMatrixx
ST. LOUIS — Express Scripts on Wednesday announced it had acquired myMatrixx, a pharmacy benefit solutions provider for the workers' compensation industry. The companies will merge core capabilities to deliver “best-in-class” clinical expertise, advanced analytics, and customized client experiences to serve workers' compensation clients and injured patients.
The combination of Express Scripts and myMatrixx will make enhanced pharmacy services offerings available to current and prospective workers' compensation clients, the companies said. The combined workers' compensation team will be led by Artemis Emslie, currently CEO of myMatrixx.
"We are proud to create best-in-class pharmacy services for workers' compensation programs by combining our deep expertise with the market-leading myMatrixx customer experience and technology," said Express Scripts president and CEO Tim Wentworth. "We are well-equipped to address our clients' evolving needs. Our unique combination of scale, technology, and a customized client experience sets the standard for workers' compensation programs."
Terms of the transaction were not disclosed. Bryan Cave and Skadden, Arps, Slate, Meagher & Flom served as legal counsel to Express Scripts. SunTrust Robinson Humphrey acted as myMatrixx's exclusive financial advisor and Akerman served as myMatrixx's legal counsel.
"myMatrixx's industry knowledge, technology and client experience have put us at the forefront of pharmacy services for workers' compensation programs," said Artemis Emslie, myMatrixx CEO. "With the demand for customized pharmacy solutions only growing, now is the right time to partner with Express Scripts and leverage the size and scale of the nation's largest PBM to benefit our clients."
With more than 83 million members, Express Scripts said it brings an ability to invest resources into advanced analytics. Express Scripts will leverage its clinical expertise innovation, client services, and strong marketplace footprint on behalf of its workers' compensation program. myMatrixx's strong reputation in the market for client services and agility will generate new growth opportunities and the combination will create more customer value, the companies said.
Fred’s makes $38K donation to American Heart Association
MEMPHIS, Tenn. — Fred’s Pharmacy’s heart disease and colorectal cancer awareness campaigns culminated in the Memphis-based retailer making a $38,244 donation to the American Heart Association earlier this month, bringing the total donated over the last four years to $130,703.
"More than 11% of adults are diagnosed with heart disease every year," said Fred’s EVP and COO healthcare, Tim Leibmann. "When it comes to colon cancer, incidence and death rates are higher than the national average in many of our geographic markets. We're proud to bring much needed awareness of these diseases to our local communities by providing information, free blood pressure screenings and free at-home colon cancer screening kits for our customers."
Each year, more than 27 million Americans are diagnosed with heart disease. Recognizing the importance of early detection, Fred’s offers free blood pressure screenings every day. Since February 2014, the retailer has partnered with the American Heart Association for American Heart Month, donating $1 to the AHA for each blood pressure screening given at pharmacy locations during the month.
Another deadly disease, colorectal cancer, is the second leading cause of cancer deaths in the United States for cancers affecting both men and women. For the fifth consecutive year, Fred’s recognized March as Colon Cancer Awareness Month by giving away free at-home EZ Detect screening kits that can detect signs of colon cancer and rectal cancer in the early stages, when they are most treatable. Fred’s partnered with media outlets to get the word out about the free kits. By the end of the month-long campaign, 60,000 Fred’s customers had received screening kits.
Fred’s operates 601 pharmacy and general merchandise stores and three specialty pharmacy-only locations, including 14 franchised Fred’s locations.
FDA approves hypertension generic
MUMBAI, India — Jubilant Life Sciences announced that Jubilant Pharma, a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has received Food and Drug Administration Abbreviated New Drug Application final approval for amlodipine and olmesartan medoxomil Tablets 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg, the generic version of Daiichi Sankyo’s Azor.
The drug is used for the treatment of hypertension. According to Jubilant, the FDA approval is the third the company has received during its current financial year. As of Dec. 31, Jubilant Life Sciences had a total of 73 ANDAs for oral solids filed in the United States, of which 49 have been approved.
India-based Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma, is engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products via six FDA-approved manufacturing facilities in India, the USA and Canada.